Description
Book SynopsisPart I. Why Consider Focal Therapy?.- 1. What is Focal Therapy for Prostate Cancer? A Guide for Patients.- 2. Evolution of Focal Therapy for Localized Breast Cancer: Lumpectomy.- 3. Image-targeted Therapy for Localized Kidney Cancer.- 4. The Patient's Perspective: What Does the Patient Want? .- Part II. Global Perspective of Active Surveillance (AS) and Focal Therapy (FT) .- 5. Intersection of AS and Radical Therapy: Opportunities for FT in North America..- 6. FT and AS of Prostate Cancer - A European Perspective.- 7. FT and AS of Prostate Cancer in Southeast Asia and the East.- 8. FT Perception and Acceptance in South America.- Part III. The Focal Therapy Concept: Scientific Foundation.- 9. Understanding Tumor Biology and Pathology - Cancer Grade, Volume, and Spatial Location as a Foundation for Focal Therapy.- 10. Identifying and Characterizing the Index Lesion.- 11. The Role of Molecular Techniques to Distinguish Low Grade from Lethal Cancers.- 12. Utilizing Biopsy-based Genomic Assays to Risk Stratify Patients for Active Treatment.- 13. Can Understanding and Utilizing the Tumor Microenvironment Enhance the Therapeutic Efficacy of FT? .- 14. Differences between MRI Visible vs Invisible Cancers: Biology and Outcomes.- Part IV. Prostate Imaging and Staging.- 15. PIRADS Reporting Standards and Limitations for Cancer Detection in the Peripheral Zone vs Transition Zone, PI-QUAL, and Standardization in MR Quality.- 16. Employing a Quality Improvement Program to Optimize mpMRI-directed Fusion Biopsy.- 17. Multiparametric Ultrasound for Prostate Imaging and Targeting.- 18. What is Necessary for FT Staging: Cross-sectional vs PET vs Nil?.- Part V. Image-Targeted Prostate Biopsy Techniques.- 19. mpMRI-TRUS Prostate Fusion Biopsy Commercial Systems.-20. Comparison of Outcomes with Transperineal vs Transrectal Image-targeted Prostate Biopsy.- 21. Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize and Treat the mpMRI Invisible Lesion.- 22. Multi-parametric Ultrasound (mpUS) Biopsy.- 23. Diagnostic Performance of PET-based Targeted Fusion Biopsy in Prostate Cancer.- 24. Optimizing biopsy core quality for diagnosis.- Part VI. Patient Selection and Ablation Treatment Schema.- 25. Patient Selection: What Tumors Should Be Treated Based on Grade, Size, Location, Genetics and Risk Category?.- 26. Definitions and Common Terminology for Focal Prostate Ablation.- 27. Focal Therapy for Anterior Cancers.- 28. Office-based Outpatient Focal Therapy.- Part VII. Transperineal Technologies for Focal Therapy.- 29. Focal Brachytherapy and IMRT.- 30. In-bore Transperineal MRI-Guided Laser Ablation.- 31. Focal Cryoablation.- 32. Irreversible Electroporation for Partial Gland Ablation: Clinical Application and Outcomes.- 33. Photodynamic Therapy.- Part VIII. Transurethral Technologies for Focal Therapy.- 34. Role of TULSA as a Focal Therapy in Prostate Cancer.- 35. Transurethral Vapor Ablation in Prostate Cancer.- Part IX. Transrectal Technologies for Focal Therapy.- 36. Robotic High-Intensity Focused Ultrasound.- 37. Transrectal laser ablation of prostate cancer.- Part X. Post-treatment Assessment of Focal Therapy Outcomes.- 38. Role of Prostate MRI for Post-treatment Assessment and Surveillance.- 39. Measuring patient-based outcomes: setting realistic expectations when balancing functional outcomes with cancer control.- 40. Assessing Functional Outcomes after Focal Therapy.- 41. Biochemical Assessment of Cancer Outcomes following Focal Therapy.- 42. Pathologic Assessment and Implications following Prostate Focal Therapy.- 43. Salvage Options after Focal Therapy Recurrence.- Part XI. Looking forward.- 44. Design of Payment and Reimbursement Strategies for Focal Therapy for Acceptance in Value Based Care Models.- 45. The Horizon: Future of Focal Therapy in Prostate Cancer.
